Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Researchers reported findings from several studies focusing on HER2-positive breast cancer during the American Society of Clinical Oncology's 2015 annual meeting. The studies focused on an oral therapy, neratinib, being studied in early-stage and metastatic breast cancer, as well as different ways to treat breast cancer that is both HER2- and hormone-positive.
Studies presented at the 2015 meeting of the American Society of Clinical Oncology (ASCO) included several on triple-negative breast cancer. We report on a trial of enzalutamide, an androgen receptor inhibitor medicine, and a study of maintenance chemotherapy in people with early-stage, hormone receptor-negative breast cancer.
On Monday, at the American Society of Clinical Oncology (ASCO) meeting, in Chicago, oral presentations of breast cancer studies took place. Read about the latest findings related to breast cancer that is hormone receptor-positive.
Our first report from the 2015 annual meeting of the American Society of Clinical Oncology covers a possibly practice-changing study on surgery in early-stage breast cancer, and a novel treatment to prevent hair loss caused by chemotherapy.
A study looked at hundreds of thousands of women with a history of breast cancer. It found that how likely a woman was to be diagnosed with stage I breast cancer varied depending on her race or ethnicity. Women of Japanese descent were most likely to be diagnosed at stage I. The risk levels of Hispanic and non-Hispanic white women and of women of other Asian descent fell in the middle. Black women were the least likely to be diagnosed with stage I disease.
Obesity, Extensive Surgery and Removal of Many Lymph Nodes Put Women With Breast Cancer at Higher Risk for Lymphedema
A study that followed women diagnosed with breast cancer in the ’90s for about a decade found several factors influenced their risk of developing lymphedema. These included age, race, weight, stage of cancer and types of treatment given.
Researchers looked at two past studies on how well the chemotherapy medicines gemcitabine (Gemzar) and capecitabine (Xeloda) work when each one is paired with another chemotherapy medicine called docetaxel (Taxotere). They found that the two combinations worked similarly well, but people who took the capecitabine-docetaxel combo were more likely to stop their therapy because of side effects.
Researchers found that a high number of African-American women don’t start taking hormonal therapy within the first year after a hormone-positive breast cancer diagnosis. These results may partly explain why African-American women have worse breast cancer outcomes than white women.
A study looking at differences between tamoxifen-only treatment and tamoxifen plus ovarian function suppression, or OFS, in certain premenopausal women with early-stage breast cancer, found the OFS group experienced more difficulty with menopausal symptoms and other side effects.
A small, stage I/II study found that giving the anti-cancer medicines neratinib and capecitabine at the same time may help people with HER2-positive metastatic breast cancer that is no longer responding to standard treatment.